HealthPharma focus on weight-loss drugs could put insulin supply at risk, experts warn
The Access to Medicine Foundation warns that pharmaceutical companies’ rush into GLP-1 weight-loss drugs could draw attention away from insulin and other diabetes treatments. Its report says many people in poorer countries cannot obtain basic insulin, while GLP-1 drugs remain inaccessible in many markets. Higher profits from weight-loss treatments could also put insulin supply at risk.
Pharma focus on weight-loss drugs could put insulin supply at risk, experts warn
Health